Highlights Neurizon Therapeutics Limited

Equities

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:26:53 18/07/2025 am IST			5-day change	1st Jan Change
0.1600 ^AUD	+3.23%		0.00%	-5.88%

10/07	Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial	MT
03/07	Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	MT

Highlights

Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial	10/07	MT
Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	03/07	MT
Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	02/07	MT
Neurizon® Therapeutics Limited Announces New Preclinical Data Demonstrating Significant Neuroprotective Effects of Nuz-001 Sulfone	16/06	CI
Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line	04/04	MT
Neurizon Therapeutics Limited Announces Results from an Additional Independent Study Carried Out in Partnership with the University of Queensland	04/04	CI
Neurizon Therapeutics Limited Announces Results from an Independent Study Conducted in Collaboration with Tessara Therapeutics	01/04	CI
Neurizon Therapeutics Limited Provides Update on Preparation for Entry into the Healey & AMG Center	24/03	CI
Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%	17/03	MT
Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2024	17/02	CI
Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%	05/02	MT
Neurizon Therapeutics Says US Patent Granted For NUZ-001	05/02	RE
Neurizon Files Investigational New Drug Application with US FDA for Amyotrophic Lateral Sclerosis Trial; Shares Down 3%	18/12	MT
Neurizon Files IND Application to Support HEALEY ALS Platform Trial	18/12	CI
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study	19/11	CI
Neurizon Reports Positive Results from Preclinical Study of Amyotrophic Lateral Sclerosis Treatment Candidate; Shares fall 4%	18/11	MT
PharmAust Changes Name to Neurizon Therapeutics	15/24/15	MT
PharmAust Receives Nearly AU$890,000 Tax Rebate	09/24/09	MT
PharmAust Files Orphan Medicinal Product Designation for Sclerosis Treatment Following Regulatory Guidance	17/24/17	MT
PharmAust Limited Reports Earnings Results for the Full Year Ended June 30, 2024	30/24/30	CI
PharmAust Secures SME Status with European Medicines Agency	01/24/01	MT
PharmAust to Raise AU$10 Million in Placement; to Open Share Purchase Plan; Shares Fall 8%	21/24/21	MT
PharmAust Obtains Orphan Drug Designation for Monepantel; Shares Up 5%	17/24/17	MT
PharmAust Obtains Approval to Commence Monepantel Extension Study	10/24/10	MT
PharmAust Submits Supporting Data to US FDA for Monepantel Orphan Drug Designation Request; Shares Down 7%	14/24/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neurizon Therapeutics Limited

Equities

NUZ

AU0000357261

Pharmaceuticals

Highlights

Filters